Humoral and cellular responses after a third dose of BNT162b2vaccine in patients with lymphoid malignancies

[JIDD]

assets.researchsquare.com/f...

Daniel Re, Centre Hospitalier, Antibes et al

"CONCLUSIONS

Dose 3 of BNT162b2 vaccine stimulated humoral immune response among patients with LM, in particular patients with MM (who had higher anti-S baseline titer after dose 2) and those with no anti-CD20 treatment history within a year. T-cell response was increased among patients in particular with no active chemotherapy regimen. Our data support the use of an early third vaccine

dose among immunocompromised patients followed for LM though some of them will still have vaccine failure"

[HopeME]

What does “followed for LM mean”? Thanks

[johnl in reply to HopeME]

lymphoid malignancies (LM),

john

[AussieNeil Partner Administrator in reply to HopeME]

LM = Lymphoid Malignancy

BNT162b2 is the mRNA COVID-19 vaccine Tozinameran, more commonly known as the Pfizer vaccine, developed by BioNTech.

4 of the 9 CLL patients in the study (31%) had a SARS-CoV-2 anti-S antibody response of ≥0.8 U/mL

[Youngen]

Thanks for sharing!

At least this addresses the safety of the third shot. No adverse events.

Can’t say I’m happy to read the results although I am not very surprised and happy to take my chances and hope for the best!

[bennevisplace]

This is another piece of the jigsaw puzzle. The authors admit its limitations, but do endorse booster shots for blood cancer patients overall. The effect on cellular response was, if anything, more marked than on humoral response.

This is not the first study to find no response in patients treated with a CD20 mAb less than 12 months previously (Tel Aviv did too, for spike antibody level).

Thanks for sharing.